Table 4 Impact of observation period and disease definition on resulting figures of comorbid CVD in patients with T2D
Observation intervall | % of T2D patients with CVD | |||||
|---|---|---|---|---|---|---|
Narrow definition | Narrow definition including CHF | Wide definition | ||||
% | 95% CI | % | 95% CI | % | 95% CI | |
2010–2015 | 46.7 | (46.52; 46.86) | 54 | (53.83; 54.17) | 57.1 | (56.9; 57.24) |
2011–2015 | 45.3 | (45.1; 45.44) | 52.6 | (52.44; 52.78) | 55.6 | (55.44; 55.78) |
2012–2015 | 43.7 | (43.53; 43.87) | 51 | (50.87; 51.21) | 54 | (53.81; 54.15) |
2013–2015 | 41.9 | (41.75; 42.09) | 49.2 | (49.03; 49.37) | 52 | (51.86; 52.21) |
2014–2015 | 39.7 | (39.56; 39.9) | 46.8 | (46.63; 46.97) | 49.6 | (49.41; 49.75) |
2015 | 36.8 | (36.63; 36.96) | 43.5 | (43.29; 43.63) | 46.2 | (46.03; 46.38) |